Physician profile
Matthew E Levine
NPI 1053621078
$2,362.44
in general payments reported to CMS, 2019-2025
11 companies · $222 in 2025
The $222 reported for 2025 was less than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $202 · 2020: $145 · 2021: $70.12 · 2022: $200 · 2023: $1,148 · 2024: $375 · 2025: $222.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,157 · Travel and Lodging: $588.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,157.27 |
| Travel and Lodging | $587.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Microport Orthopedics INC | $1,075.63 | 2023 | Mpo Medial Pivot Knee |
| Smith+Nephew, INC. | $621.15 | 2019-2025 | Real Intelligence, Journey II, Anthology |
| Linkbio Corp | $184.80 | 2024 | |
| Arthrex, INC. | $151.20 | 2022 | |
| Stryker Corporation | $144.56 | 2020 | |
| Next Science LLC | $57.13 | 2021 | |
| Amgen INC. | $48.66 | 2019 | |
| Innovation Technologies INC | $37.38 | 2021-2024 | Irrisept |
| Edwards Lifesciences Corporation | $16.65 | 2022 | |
| Heron Therapeutics, INC. | $16.06 | 2024 | Zynrelef |
| Vivus LLC | $9.22 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Levine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.